Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2006-10-24
2006-10-24
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S178100, C424S156100, C424S183100, C424S142100, C424S155100, C424S181100, C530S391700, C530S391900, C530S387100, C530S388150, C530S388220, C530S388800, C530S391300
Reexamination Certificate
active
07125541
ABSTRACT:
The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.
REFERENCES:
patent: 4361544 (1982-11-01), Goldenberg
patent: 4444744 (1984-04-01), Goldenberg
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 4867962 (1989-09-01), Abrams
patent: 4925922 (1990-05-01), Byers et al.
patent: 4958009 (1990-09-01), Bjorn et al.
patent: 4980457 (1990-12-01), Jansen et al.
patent: 4981953 (1991-01-01), Barbieri et al.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5024834 (1991-06-01), Houston et al.
patent: 5057313 (1991-10-01), Shih et al.
patent: 5081034 (1992-01-01), Bevilacqua et al.
patent: 5120525 (1992-06-01), Goldenberg
patent: 5191067 (1993-03-01), Lappi et al.
patent: 5308622 (1994-05-01), Casscells et al.
patent: 5342757 (1994-08-01), Garin-Chesa et al.
patent: 5354778 (1994-10-01), Ray et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5403713 (1995-04-01), Bevilacqua et al.
patent: 5504067 (1996-04-01), Morrissey et al.
patent: 5576288 (1996-11-01), Lappi et al.
patent: 5589363 (1996-12-01), Roy et al.
patent: 5632991 (1997-05-01), Gimbrone, Jr.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5659013 (1997-08-01), Senger et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5677181 (1997-10-01), Parish
patent: 5679637 (1997-10-01), Lappi et al.
patent: 5716595 (1998-02-01), Goldenberg
patent: 5719120 (1998-02-01), Letarte et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5830448 (1998-11-01), Vehar
patent: 5830847 (1998-11-01), Letarte et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 5866127 (1999-02-01), Senger et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5874081 (1999-02-01), Parish
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5922688 (1999-07-01), Hung et al.
patent: 5928641 (1999-07-01), Seon
patent: 5942602 (1999-08-01), Wels et al.
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 6004554 (1999-12-01), Thorpe et al.
patent: 6015693 (2000-01-01), Letarte et al.
patent: 6022541 (2000-02-01), Senger et al.
patent: 6037329 (2000-03-01), Baird et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6107090 (2000-08-01), Bander
patent: 6129915 (2000-10-01), Wels et al.
patent: 6136311 (2000-10-01), Bander
patent: 6150508 (2000-11-01), Murphy et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6190660 (2001-02-01), Seon
patent: 6200566 (2001-03-01), Seon
patent: 6261535 (2001-07-01), Thorpe et al.
patent: 6451312 (2002-09-01), Thorpe
patent: 6582959 (2003-06-01), Kim
patent: 2002/0001566 (2002-01-01), Rajopadhye et al.
patent: 2002/0098187 (2002-07-01), Ferrara et al.
patent: 2003/0086919 (2003-05-01), Rosenblum et al.
patent: 2003/0124147 (2003-07-01), Vallera et al.
patent: 2003/0129223 (2003-07-01), Wartchow et al.
patent: 2003/0133972 (2003-07-01), Danthi et al.
patent: 2003/0180305 (2003-09-01), Rajopadhye et al.
patent: 2003/0190317 (2003-10-01), Baca et al.
patent: 2003/0203409 (2003-10-01), Kim
patent: 2003/0206899 (2003-11-01), Ferrara et al.
patent: 2004/0013640 (2004-01-01), Zardi et al.
patent: 0 359 347 (1990-03-01), None
patent: 0666868 (1994-11-01), None
patent: 0 458 878 (1996-09-01), None
patent: 0 484 401 (1996-09-01), None
patent: 0 255 424 (1998-02-01), None
patent: 0 938 505 (2002-03-01), None
patent: 0 666 868 (2002-04-01), None
patent: 0 669 988 (2003-09-01), None
patent: WO 81/01145 (1981-04-01), None
patent: WO 90/03801 (1990-04-01), None
patent: WO 90/05539 (1990-05-01), None
patent: WO 90/12585 (1990-11-01), None
patent: WO 90/13300 (1990-11-01), None
patent: WO 90/13649 (1990-11-01), None
patent: WO 91/05806 (1991-05-01), None
patent: WO 91/07941 (1991-06-01), None
patent: WO 92/01470 (1992-02-01), None
patent: WO 92/12729 (1992-08-01), None
patent: WO 92/14748 (1992-09-01), None
patent: WO 92/19646 (1992-11-01), None
patent: WO 93/08210 (1993-04-01), None
patent: WO 93/08473 (1993-04-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 94/05328 (1994-03-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/11499 (1994-05-01), None
patent: WO 95/21868 (1995-08-01), None
patent: WO 97/45544 (1997-12-01), None
patent: WO 98/43678 (1998-10-01), None
patent: WO 99/58570 (1999-11-01), None
patent: WO/US00/34337 (2000-06-01), None
patent: WO 01/54723 (2001-08-01), None
patent: WO 03/033514 (2003-04-01), None
patent: WO 03/057831 (2003-07-01), None
Osborn et al., “Leukocyte Adhesion to Endothelium in Inflammation,”Cell, 62:3-6, 1990.
June et al., “Role of the CD28 Receptor in T-Cell Activation,”Immunology Today, 11(6):211-216, 1990.
Denekamp, “Vascular Attack as a Therapeutic Strategy for Cancer,”Cancer and Metastasis Reviews, 9:267-282, 1990.
Scott et al., “Anti-CD3 Antibody Induces Rapid Expression of Cytokine GenesIn Vivo,” The Journal of Immunology, 145(7):2183-2188, 1990.
Burrows et al., “A Murine Model for Antibody-Directed Targeting of Vascular Endothelial Cells in Solid Tumors,”Cancer Research, 52:5954-5962, Nov. 1992.
Burrows and Thorpe, “Targeting the Vasculature of Solid Tumors,”Journal of Controlled Release, 28:195-202, Jan. 1994.
Clauss et al., “A Polypeptide Factor Produced by Fibrosarcoma Cells That Induces Endothelial Tissue Factor and Enhances the Procoagulant Response to Tumor Necrosis Factor/Cachetin,”The Journal of Biological Chemistry, 265(12):7078-7083, Apr. 1990.
Thorpe and Burrows, “Antibody-Directed Targeting of the Vasculature of Solid Tumors,”Breast Cancer Research and Treatment, 36 (2):237-251, 1995.
Burgess et al., “Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-Binding Activities by Site-Directed Mutagenesis of a Single Lysine Residue,”J. Cell Biol., 111:2129-2138, 1990.
Gillies and Wesolowski, “Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities,”Hum. Antibod. Hybridomas, 1(1):47-54, 1990.
Lapierre et al., “Three Distinct Classes of Regulatory Cytokines Control Endothelial Cell MHC Antigen Expression,”J. Exp. Med., 167:794-804, 1988.
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,”Mol. Cell Biol., 8(3):1247-1252, 1988.
Qian et al., “Human Peripheral Blood Lymphocytes Targeted with Bispecific Antibodies Release Cytokines That Are Essential for Inhibiting Tumor Growth.”J. Immunol., 146(9):3250-3256, 1991.
Tao and Morrison, “Studies of Aglycosylated Chimeric Mouse-Human IgG—Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region,”J. Immunol., 143(8):2595-2601, 1989.
Waldman, Thomas A., “Monoclonal Antibodies in Diagnosis and Therapy,”Science, 252:1657-1662, 1991.
Wen et al., “Effects of γ-Interferon on Major Histocompatibility Complex Antigen Expression and Lymphocytic Infiltration in the 9L Gliosarcoma Brain Tumor Model: Implications for Strategies of Immunotherapy,”J. Neuroimmunol., 36:57-68, 1992.
Vitetta et al., “Redesigning Nature's Poisons to Create Anti-Tumor Reagents,”Science, 238:1098-1104, 1987.
Songsivilai & Lachmann, “Bispecific antibody: a tool for diagnosis and treatment of disease”,Clin.
Burrows Francis J.
Thorpe Philip E.
Chong Yong S.
Fussey Shelley P. M.
The University of Texas System & Board of Regents
Wang Shengjun
LandOfFree
Combined methods for tumor vasculature targeting and tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined methods for tumor vasculature targeting and tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined methods for tumor vasculature targeting and tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3685757